- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00360763
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
August 4, 2006 updated by: Huazhong University of Science and Technology
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension.
ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension.
The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension.
Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA.
A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.
Study Overview
Study Type
Interventional
Enrollment
600
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Department of Cardiology, Wuhan Union Hospital
-
Contact:
- Yu-Hua Liao, Doctor
- Phone Number: 00862785726376
- Email: yumiaowei@vip.sina.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Hypertension (2 grade)
Exclusion Criteria:
- Secondary hypertension
- Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Yu-Hua Liao, Union Hospital, Tongji Medical College
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002 Jul;25(4):641-6. doi: 10.1291/hypres.25.641.
- Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH; SOT-AT1 Study Group. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart. 2011 Mar;97(6):479-84. doi: 10.1136/hrt.2009.192104. Epub 2011 Feb 4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion
December 1, 2006
Study Registration Dates
First Submitted
August 4, 2006
First Submitted That Met QC Criteria
August 4, 2006
First Posted (Estimate)
August 7, 2006
Study Record Updates
Last Update Posted (Estimate)
August 7, 2006
Last Update Submitted That Met QC Criteria
August 4, 2006
Last Verified
August 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UH-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on candesartan cilexetil
-
AstraZenecaCompletedNon-diabetic Nephropathy With HypertensionKorea, Republic of
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedCardiovascular DiseaseIndia
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyTerminatedChronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) LevelGermany, France, Netherlands
-
AstraZenecaCompleted
-
TakedaCompleted
-
Ullevaal University HospitalTakeda; AstraZeneca; Southern-Eastern Norway Health Authorities RHFCompleted
-
AstraZenecaTakedaCompleted
-
TakedaCompleted